Kamel Alkhatib1,2, Tina M Poseno2, Alda Diaz Perez1,2, Jeannine M Durdik1,3, Julie A Stenken4,5. 1. Cell and Molecular Biology Program, University of Arkansas, Fayetteville, Arkansas, 72701, USA. 2. Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas, 72701, USA. 3. Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, 72701, USA. 4. Cell and Molecular Biology Program, University of Arkansas, Fayetteville, Arkansas, 72701, USA. jstenken@uark.edu. 5. Department of Chemistry and Biochemistry, University of Arkansas, Fayetteville, Arkansas, 72701, USA. jstenken@uark.edu.
Abstract
PURPOSE: The hypothesis that locally-released iloprost, a synthetic prostacyclin analog, affects macrophage phenotype at a microdialysis implant in the subcutaneous space of rats was tested. Macrophage activation towards alternatively-activated phenotypes using pharmaceutical release is of interest to improve integration of implants and direct the foreign body reaction toward a successful outcome. METHODS: Macrophage cell culture was used to test iloprost macrophage activation in vitro. Microdialysis sampling probes were implanted into the subcutaneous space of Sprague-Dawley rats to locally deliver iloprost in awake- and freely-moving rats. Monocyte chemoattractant protein -1 (CCL2) was quantified from collected dialysates using ELISA. Immunohistochemical staining was used to determine the presence of CD163+ macrophages in explanted tissues. RESULTS: Iloprost reduced CCL2 concentrations in NR8383 macrophages stimulated with lipopolysaccharide. CCL2 concentrations in collected dialysates were similarly reduced in the presence of iloprost. Iloprost caused an increase in CD163+ cells in explanted tissue surrounding implanted microdialysis probes at two days post probe implantation. CONCLUSIONS: Localized delivery of iloprost caused macrophage activation at the tissue interface of a microdialysis subcutaneous implant in rat. This model system may be useful for testing other potential macrophage modulators in vivo.
PURPOSE: The hypothesis that locally-released iloprost, a synthetic prostacyclin analog, affects macrophage phenotype at a microdialysis implant in the subcutaneous space of rats was tested. Macrophage activation towards alternatively-activated phenotypes using pharmaceutical release is of interest to improve integration of implants and direct the foreign body reaction toward a successful outcome. METHODS: Macrophage cell culture was used to test iloprost macrophage activation in vitro. Microdialysis sampling probes were implanted into the subcutaneous space of Sprague-Dawley rats to locally deliver iloprost in awake- and freely-moving rats. Monocyte chemoattractant protein -1 (CCL2) was quantified from collected dialysates using ELISA. Immunohistochemical staining was used to determine the presence of CD163+ macrophages in explanted tissues. RESULTS:Iloprost reduced CCL2 concentrations in NR8383 macrophages stimulated with lipopolysaccharide. CCL2 concentrations in collected dialysates were similarly reduced in the presence of iloprost. Iloprost caused an increase in CD163+ cells in explanted tissue surrounding implanted microdialysis probes at two days post probe implantation. CONCLUSIONS: Localized delivery of iloprost caused macrophage activation at the tissue interface of a microdialysis subcutaneous implant in rat. This model system may be useful for testing other potential macrophage modulators in vivo.
Authors: Julia Kzhyshkowska; Alexandru Gudima; Vladimir Riabov; Camille Dollinger; Philippe Lavalle; Nihal Engin Vrana Journal: J Leukoc Biol Date: 2015-07-13 Impact factor: 4.962
Authors: David M Aronoff; Camila M Peres; Carlos H Serezani; Megan N Ballinger; Jennifer K Carstens; Nicole Coleman; Bethany B Moore; R Stokes Peebles; Lucia H Faccioli; Marc Peters-Golden Journal: J Immunol Date: 2007-02-01 Impact factor: 5.422
Authors: Sebastian Wendler; Claudia Schlundt; Christian H Bucher; Jan Birkigt; Christian J Schipp; Hans-Dieter Volk; Georg N Duda; Katharina Schmidt-Bleek Journal: Front Immunol Date: 2019-04-05 Impact factor: 7.561